ROCKY MOUNT, NC--(Marketwire - May 10, 2011) - PharmStar Pharmaceuticals, Inc., (PINKSHEETS: PHAR) (the “Company”), a U.S. drug developer, manufacturer and marketer of the FDA-approved, Over-the-Counter (OTC) liquid pain reliever Aquaprin™, today announced that Company CEO Howard Phykitt will hold an investor conference call today at 4:15 pm Eastern Time to discuss the current status of the Company’s initiatives. All interested parties are invited to participate.
To join the call, please dial 712-432-3900 approximately 5 to 10 minutes before the start of the call and when prompted, enter conference code 594265#. Attendees are asked to submit any questions prior to the start of the call via email to cc@pharmstarinc.com.
Additionally, Mr. Phykitt will be featured on the Bill Chippas Show this morning, Tuesday, May 10, 2011, at 10:15 am Eastern Time. Listeners may tune into the live show by visiting http://www.billchippasshow.com.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. is a U.S.-based drug development, manufacturing and marketing company and the innovator of Aquaprin™, an FDA-approved, OTC liquid pain reliever. In development since 1993 with over $3 million invested to-date, Aquaprin™ is a liquid derivative of aspirin based on a patent-pending formula. The product is designed to dissolve nearly instantly in just 1.5 ounces of water, which can be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset. For more information, visit www.pharmstarinc.com.
Forward-Looking Statements Disclosure
This press release includes “forward-looking statements” within the meaning of the federal securities laws, commonly identified by such terms as “believes,” “will,” “looking ahead,” “anticipates,” “estimates” and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company’s projections and expectations are disclosed in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
Contact:
PharmStar, Inc.
919-794-7000
Email Contact
www.pharmstarinc.com
Investor Contact: Email Contact